Raymond James analyst Danielle Brill maintained a Buy rating on Harmony Biosciences Holdings (HRMY – Research Report) today and set a price target of $60.00. The company’s shares closed last Tuesday at $55.42, close to its 52-week high of $57.13.
According to TipRanks.com, Brill is a 5-star analyst with an average return of 12.7% and a 54.9% success rate. Brill covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Sarepta Therapeutics, and SAGE Therapeutics.
Currently, the analyst consensus on Harmony Biosciences Holdings is a Moderate Buy with an average price target of $60.50, representing an 11.6% upside. In a report issued on July 27, Mizuho Securities also maintained a Buy rating on the stock with a $64.00 price target.
Based on Harmony Biosciences Holdings’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $85.31 million and net profit of $21.49 million. In comparison, last year the company earned revenue of $59.67 million and had a net profit of $7.39 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs.
Read More on HRMY:
- Piper Sandler Maintains a Buy Rating on Sprout Social (SPT)
- Sunnova Energy International (NOVA) Gets a Hold Rating from Wells Fargo
- SVB Securities Keeps Their Buy Rating on Axcella Health (AXLA)
- Alteryx (AYX) Gets a Buy Rating from Piper Sandler
- Blueprint Medicines (BPMC) Gets a Hold Rating from SVB Securities